Risk factors for somnolence, edema, and hallucinations in early Parkinson disease
- 10 July 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 69 (2) , 187-195
- https://doi.org/10.1212/01.wnl.0000265593.34438.00
Abstract
Background: The CALM-PD trial evaluated the development of motor complications in subjects with early Parkinson disease (PD) randomized to initial treatment with either pramipexole or levodopa. A secondary finding of the trial was a higher than anticipated development or worsening of somnolence and edema and development of hallucinations.Keywords
This publication has 39 references indexed in Scilit:
- Sleep and Cardiovascular DiseaseCurrent Problems in Cardiology, 2005
- Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's diseaseMovement Disorders, 2003
- Mechanisms of pulmonary edema clearance during acute hypoxemic respiratory failure: Role of the Na,K-ATPaseCritical Care Medicine, 2003
- Comparison of the Risk of Adverse Events with Pramipexole and Ropinirole in Patients with Parkinson???s DiseaseDrug Safety, 2003
- A Randomized Controlled Trial Comparing Pramipexole with Levodopa in Early Parkinson's Disease: Design and Methods of the CALM-PD StudyClinical Neuropharmacology, 2000
- A community‐based study of sleep disorders in patients with Parkinson's diseaseMovement Disorders, 1998
- Visual Hallucinations Associated With Parkinson DiseaseArchives of Neurology, 1996
- Four‐year treatment of patients with parkinsonism using amantadine alone or with levodopaAnnals of Neurology, 1978
- “Mini-mental state”Journal of Psychiatric Research, 1975
- ParkinsonismNeurology, 1967